Simultaneous detection of nitrosamines and other sartan-related impurities in active pharmaceutical ingredients by supercritical fluid chromatography
•Simultaneous detection of nitrosamines and monographed impurities in sartans•Novel SFC approach for large group of nitrosamines•High sensitivity and selectivity within extreme short analysis time•Improved reliability and deep understanding by QbD development approach•Both NDMA and NDEA detected in...
        Saved in:
      
    
          | Published in | Journal of pharmaceutical and biomedical analysis Vol. 174; pp. 151 - 160 | 
|---|---|
| Main Authors | , | 
| Format | Journal Article | 
| Language | English | 
| Published | 
        England
          Elsevier B.V
    
        10.09.2019
     | 
| Subjects | |
| Online Access | Get full text | 
| ISSN | 0731-7085 1873-264X 1873-264X  | 
| DOI | 10.1016/j.jpba.2019.04.049 | 
Cover
| Abstract | •Simultaneous detection of nitrosamines and monographed impurities in sartans•Novel SFC approach for large group of nitrosamines•High sensitivity and selectivity within extreme short analysis time•Improved reliability and deep understanding by QbD development approach•Both NDMA and NDEA detected in Losartan API
Since July 2018, the pharmacological class of “sartans” has been the subject of considerable media and analytical interest, as it became known that they are contaminated with nitrosamines such as N-nitrosodimethylamine (NDMA), N-nitrosodiethylamine (NDEA) and N-nitrosodiisopropylamine (NDiPA). Previous compendial methods are not able to detect these new contaminants. Using the latest and innovative Quality-by-Design (QbD) approach, it has now been possible to develop an analytical method that enables to investigate sartans, such as valsartan and losartan. Also a large class of different nitrosamines in the ppb range and sartan-related impurities can thus be determined simultaneously in a single analysis using supercritical fluid chromatography (SFC). By using SFC, a broad spectrum of nonpolar and very polar impurities can be separated and analyzed in under 20 min. The analytical method developed is validated for limit testing according to ICH Q2(R1) and fulfills default thresholds of EMA and FDA for testing of drug substances and genotoxic impurities. Additionally, it can also be adapted to other pharmaceuticals that may be contaminated with nitrosamines, since tetrazole synthesis as the underlying cause of nitrosamine contamination is important for a set of other non-sartan drug substances. | 
    
|---|---|
| AbstractList | Since July 2018, the pharmacological class of "sartans" has been the subject of considerable media and analytical interest, as it became known that they are contaminated with nitrosamines such as N-nitrosodimethylamine (NDMA), N-nitrosodiethylamine (NDEA) and N-nitrosodiisopropylamine (NDiPA). Previous compendial methods are not able to detect these new contaminants. Using the latest and innovative Quality-by-Design (QbD) approach, it has now been possible to develop an analytical method that enables to investigate sartans, such as valsartan and losartan. Also a large class of different nitrosamines in the ppb range and sartan-related impurities can thus be determined simultaneously in a single analysis using supercritical fluid chromatography (SFC). By using SFC, a broad spectrum of nonpolar and very polar impurities can be separated and analyzed in under 20 min. The analytical method developed is validated for limit testing according to ICH Q2(R1) and fulfills default thresholds of EMA and FDA for testing of drug substances and genotoxic impurities. Additionally, it can also be adapted to other pharmaceuticals that may be contaminated with nitrosamines, since tetrazole synthesis as the underlying cause of nitrosamine contamination is important for a set of other non-sartan drug substances. Since July 2018, the pharmacological class of "sartans" has been the subject of considerable media and analytical interest, as it became known that they are contaminated with nitrosamines such as N-nitrosodimethylamine (NDMA), N-nitrosodiethylamine (NDEA) and N-nitrosodiisopropylamine (NDiPA). Previous compendial methods are not able to detect these new contaminants. Using the latest and innovative Quality-by-Design (QbD) approach, it has now been possible to develop an analytical method that enables to investigate sartans, such as valsartan and losartan. Also a large class of different nitrosamines in the ppb range and sartan-related impurities can thus be determined simultaneously in a single analysis using supercritical fluid chromatography (SFC). By using SFC, a broad spectrum of nonpolar and very polar impurities can be separated and analyzed in under 20 min. The analytical method developed is validated for limit testing according to ICH Q2(R1) and fulfills default thresholds of EMA and FDA for testing of drug substances and genotoxic impurities. Additionally, it can also be adapted to other pharmaceuticals that may be contaminated with nitrosamines, since tetrazole synthesis as the underlying cause of nitrosamine contamination is important for a set of other non-sartan drug substances.Since July 2018, the pharmacological class of "sartans" has been the subject of considerable media and analytical interest, as it became known that they are contaminated with nitrosamines such as N-nitrosodimethylamine (NDMA), N-nitrosodiethylamine (NDEA) and N-nitrosodiisopropylamine (NDiPA). Previous compendial methods are not able to detect these new contaminants. Using the latest and innovative Quality-by-Design (QbD) approach, it has now been possible to develop an analytical method that enables to investigate sartans, such as valsartan and losartan. Also a large class of different nitrosamines in the ppb range and sartan-related impurities can thus be determined simultaneously in a single analysis using supercritical fluid chromatography (SFC). By using SFC, a broad spectrum of nonpolar and very polar impurities can be separated and analyzed in under 20 min. The analytical method developed is validated for limit testing according to ICH Q2(R1) and fulfills default thresholds of EMA and FDA for testing of drug substances and genotoxic impurities. Additionally, it can also be adapted to other pharmaceuticals that may be contaminated with nitrosamines, since tetrazole synthesis as the underlying cause of nitrosamine contamination is important for a set of other non-sartan drug substances. •Simultaneous detection of nitrosamines and monographed impurities in sartans•Novel SFC approach for large group of nitrosamines•High sensitivity and selectivity within extreme short analysis time•Improved reliability and deep understanding by QbD development approach•Both NDMA and NDEA detected in Losartan API Since July 2018, the pharmacological class of “sartans” has been the subject of considerable media and analytical interest, as it became known that they are contaminated with nitrosamines such as N-nitrosodimethylamine (NDMA), N-nitrosodiethylamine (NDEA) and N-nitrosodiisopropylamine (NDiPA). Previous compendial methods are not able to detect these new contaminants. Using the latest and innovative Quality-by-Design (QbD) approach, it has now been possible to develop an analytical method that enables to investigate sartans, such as valsartan and losartan. Also a large class of different nitrosamines in the ppb range and sartan-related impurities can thus be determined simultaneously in a single analysis using supercritical fluid chromatography (SFC). By using SFC, a broad spectrum of nonpolar and very polar impurities can be separated and analyzed in under 20 min. The analytical method developed is validated for limit testing according to ICH Q2(R1) and fulfills default thresholds of EMA and FDA for testing of drug substances and genotoxic impurities. Additionally, it can also be adapted to other pharmaceuticals that may be contaminated with nitrosamines, since tetrazole synthesis as the underlying cause of nitrosamine contamination is important for a set of other non-sartan drug substances.  | 
    
| Author | Schmidt, Alexander H. Schmidtsdorff, Sebastian  | 
    
| Author_xml | – sequence: 1 givenname: Sebastian surname: Schmidtsdorff fullname: Schmidtsdorff, Sebastian email: sebastian.schmidtsdorff@chromicent.de organization: Chromicent GmbH, Johann-Hittorf-Str. 8, 12489 Berlin, Germany – sequence: 2 givenname: Alexander H. surname: Schmidt fullname: Schmidt, Alexander H. organization: Chromicent GmbH, Johann-Hittorf-Str. 8, 12489 Berlin, Germany  | 
    
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31174128$$D View this record in MEDLINE/PubMed | 
    
| BookMark | eNp9kU1r3DAQhkVJaTZp_0APRcdevNXIH7KhlxLSDwj00BZ6E2NpnNViW64kB_aH9P9WZtMeeggMSDDPM4f3vWIXs5-Jsdcg9iCgeXfcH5ce91JAtxdVnu4Z20GrykI21c8LthOqhEKJtr5kVzEehRA1dNULdlkCqApku2O_v7lpHRPO5NfILSUyyfmZ-4HPLgUfcXIzRY6z5T4dKPCIIeNFoBETWe6mZQ0uucy4mWO2H4gvBwwTGlqTMzjmxX0g62hOkfcnHteFgtmkbTmMq7PcHIKfMPn7gMvh9JI9H3CM9OrxvWY_Pt5-v_lc3H399OXmw11hyrpJBVjVKCLVVdK2gtpa4YBS2baXZKjsoG3qTghAZeyQP6K3tuks1FBXtgYsr9nb890l-F8rxaQnFw2N4zkPLWUloSnzpYy-eUTXfiKrl-AmDCf9N8oMyDNgcmox0PAPAaG3vvRRb33prS8tqjxdltr_JOMSbg2kgG58Wn1_VikH9OAo6GhyxCYHHXKJ2nr3lP4HiPu1SA | 
    
| CitedBy_id | crossref_primary_10_1002_elps_202000303 crossref_primary_10_1016_j_jpba_2022_115071 crossref_primary_10_1016_j_talanta_2022_124102 crossref_primary_10_1002_jssc_202400277 crossref_primary_10_52711_2231_5675_2023_00005 crossref_primary_10_1002_bmc_6040 crossref_primary_10_1016_j_microc_2022_107341 crossref_primary_10_1021_acs_chemrestox_4c00234 crossref_primary_10_19127_bshealthscience_1377252 crossref_primary_10_22270_jddt_v10i6_s_4444 crossref_primary_10_1016_j_talanta_2020_121659 crossref_primary_10_1016_j_jpba_2021_114458 crossref_primary_10_1002_jssc_202200225 crossref_primary_10_1080_10408398_2020_1803790 crossref_primary_10_1016_j_jpba_2021_113960 crossref_primary_10_1098_rsos_220250 crossref_primary_10_1002_rcm_9432 crossref_primary_10_1002_ardp_202200484 crossref_primary_10_1016_j_xphs_2022_11_029 crossref_primary_10_3390_ijms232012125 crossref_primary_10_1080_10408347_2020_1788375 crossref_primary_10_1016_j_trac_2021_116486 crossref_primary_10_1016_j_xphs_2024_11_003 crossref_primary_10_1080_10408347_2022_2032587 crossref_primary_10_1007_s00216_024_05580_7 crossref_primary_10_22159_ijap_2024v16i5_51376 crossref_primary_10_1002_jssc_202300214 crossref_primary_10_1016_j_aca_2020_07_076 crossref_primary_10_1186_s40543_020_00254_2 crossref_primary_10_1002_dta_3635 crossref_primary_10_1016_j_jpba_2023_115685 crossref_primary_10_1016_j_microc_2020_105594 crossref_primary_10_1016_j_yrtph_2023_105355 crossref_primary_10_1080_10408347_2021_2008226 crossref_primary_10_1016_j_xphs_2023_01_005 crossref_primary_10_1093_jaoacint_qsab100 crossref_primary_10_1016_j_jpba_2020_113460 crossref_primary_10_1016_j_jpbao_2023_100020 crossref_primary_10_1016_j_jchromb_2023_123593 crossref_primary_10_2139_ssrn_4057039 crossref_primary_10_1002_bkcs_12085 crossref_primary_10_46239_ejbcs_1366734 crossref_primary_10_1016_j_cjac_2022_100150 crossref_primary_10_1080_10408347_2023_2253321 crossref_primary_10_1016_j_aca_2021_338568 crossref_primary_10_1016_j_chroma_2023_464416 crossref_primary_10_5937_arhfarm74_49565 crossref_primary_10_1016_j_chroma_2025_465741  | 
    
| Cites_doi | 10.1021/es5001352 10.1080/19440049.2010.508184 10.1080/15287394.2018.1460782 10.1016/j.jpba.2015.03.007 10.1016/j.chroma.2012.07.043 10.1016/j.chroma.2018.09.044 10.1016/j.jhazmat.2016.02.048 10.1016/j.jpba.2018.11.010  | 
    
| ContentType | Journal Article | 
    
| Copyright | 2019 Elsevier B.V. Copyright © 2019 Elsevier B.V. All rights reserved.  | 
    
| Copyright_xml | – notice: 2019 Elsevier B.V. – notice: Copyright © 2019 Elsevier B.V. All rights reserved.  | 
    
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8  | 
    
| DOI | 10.1016/j.jpba.2019.04.049 | 
    
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic  | 
    
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic  | 
    
| DatabaseTitleList | MEDLINE MEDLINE - Academic  | 
    
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database  | 
    
| DeliveryMethod | fulltext_linktorsrc | 
    
| Discipline | Pharmacy, Therapeutics, & Pharmacology | 
    
| EISSN | 1873-264X | 
    
| EndPage | 160 | 
    
| ExternalDocumentID | 31174128 10_1016_j_jpba_2019_04_049 S0731708518328723  | 
    
| Genre | Journal Article | 
    
| GroupedDBID | --- --K --M .~1 0R~ 1B1 1RT 1~. 1~5 4.4 457 4G. 5GY 5VS 7-5 71M 8P~ 9JM 9JN AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AARLI AATCM AAXUO ABFRF ABJNI ABMAC ABYKQ ABZDS ACDAQ ACGFO ACGFS ACIUM ACRLP ADBBV ADECG ADEZE AEBSH AEFWE AEKER AENEX AFKWA AFTJW AFXIZ AFZHZ AGHFR AGUBO AGYEJ AIEXJ AIKHN AITUG AJOXV AJSZI ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ AXJTR BKOJK BLXMC C45 CS3 DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FIRID FLBIZ FNPLU FYGXN G-Q GBLVA IHE J1W KOM M34 M36 M41 MO0 N9A O-L O9- OAUVE OGGZJ OVD OZT P-8 P-9 P2P PC. Q38 RIG RNS ROL RPZ SCC SCH SDF SDG SDP SES SPC SPCBC SSK SSP SSZ T5K TEORI YK3 ~G- 29L 53G AAQXK AATTM AAXKI AAYWO AAYXX ABFNM ABWVN ABXDB ACLOT ACNNM ACRPL ACVFH ADCNI ADMUD ADNMO AEIPS AEUPX AFJKZ AFPUW AGQPQ AHHHB AIGII AIIUN AJQLL AKBMS AKRWK AKYEP ANKPU APXCP ASPBG AVWKF AZFZN CITATION EFKBS FEDTE FGOYB G-2 HMT HMU HVGLF HZ~ R2- SCB SEW SPT WUQ XPP ~HD CGR CUY CVF ECM EIF NPM 7X8  | 
    
| ID | FETCH-LOGICAL-c356t-1d767ee7942d80e857afa27d8b2ece3918659001a7cdf9000bdd69d15154d51a3 | 
    
| IEDL.DBID | .~1 | 
    
| ISSN | 0731-7085 1873-264X  | 
    
| IngestDate | Sat Sep 27 22:06:43 EDT 2025 Wed Feb 19 02:32:11 EST 2025 Wed Oct 01 02:02:37 EDT 2025 Thu Apr 24 23:07:14 EDT 2025 Fri Feb 23 02:25:41 EST 2024  | 
    
| IsPeerReviewed | true | 
    
| IsScholarly | true | 
    
| Keywords | Nitrosamines Sartans Quality-by-Design (QbD) Supercritical fluid chromatography (SFC)  | 
    
| Language | English | 
    
| License | Copyright © 2019 Elsevier B.V. All rights reserved. | 
    
| LinkModel | DirectLink | 
    
| MergedId | FETCHMERGED-LOGICAL-c356t-1d767ee7942d80e857afa27d8b2ece3918659001a7cdf9000bdd69d15154d51a3 | 
    
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23  | 
    
| PMID | 31174128 | 
    
| PQID | 2242163391 | 
    
| PQPubID | 23479 | 
    
| PageCount | 10 | 
    
| ParticipantIDs | proquest_miscellaneous_2242163391 pubmed_primary_31174128 crossref_primary_10_1016_j_jpba_2019_04_049 crossref_citationtrail_10_1016_j_jpba_2019_04_049 elsevier_sciencedirect_doi_10_1016_j_jpba_2019_04_049  | 
    
| ProviderPackageCode | CITATION AAYXX  | 
    
| PublicationCentury | 2000 | 
    
| PublicationDate | 2019-09-10 | 
    
| PublicationDateYYYYMMDD | 2019-09-10 | 
    
| PublicationDate_xml | – month: 09 year: 2019 text: 2019-09-10 day: 10  | 
    
| PublicationDecade | 2010 | 
    
| PublicationPlace | England | 
    
| PublicationPlace_xml | – name: England | 
    
| PublicationTitle | Journal of pharmaceutical and biomedical analysis | 
    
| PublicationTitleAlternate | J Pharm Biomed Anal | 
    
| PublicationYear | 2019 | 
    
| Publisher | Elsevier B.V | 
    
| Publisher_xml | – name: Elsevier B.V | 
    
| References | Lim, Roh, Kim (bib0100) 2018; 81 U.S. Food & Drug Administration (bib0020) 2018 Hu, Shih, Liu, Chiang, Chen, Chao (bib0120) 2016; 310 World Health Organization (bib0040) 2002 International Agency for Research on Cancer (bib0035) 1978; vol. 17 Schmidtsdorff, Schmidt, Parr (bib0125) 2018; 1577 Sung, Kwak, Park (bib0115) 2010; 27 Venkatesan, Pycke, Halden (bib0110) 2014; 48 European Pharmacopoeia. 9th edition. Strasbourg: Council of Europe. Guideline, ICH Harmonised Tripartite - Proceedings of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, Geneva, Switzerland. (bib0095) 2017; vol 2 Barnett, McGregor, Martin (bib0085) 2016; 42 Dispas, Lebrun, Sassiat (bib0075) 2012; 1256 Abdel-Tawab, Gröner, Kopp, Meins, Wübert (bib0025) 2018; 158 Committee for Medicinal Products for Human Use (16. July 2018) CHMP List of questions - To be addressed by the API manufacturers for valsartan-containing medicinal products (Procedure number: EMEA/H/A-31/1471). European Medicines Agency - London, United Kingdom FDA updates on angiotensin II receptor blocker (ARB) recalls including valsartan, losartan and irbesartan. Galaon, Cruceru, Petre, Pascu, Iancu, Niculescu (bib0105) 2016; 17 European network of OMCLs (bib0145) 2018 EMA/703416/2018 (bib0030) 2018 . Buschmann, Holzgrabe (bib0015) 2019; 159 EDQM Knowledge Database (bib0135) 2018 European network of OMCLs (bib0060) 2018 Parr, Joseph (bib0150) 2019; 164 (Last accessed: 01. April 2019). U.S. Environmental Protection Agency, Federal Facilities Restoration and Reuse Office (bib0045) 2017 RIS.World Online (bib0130) 2018 U.S. Food & Drug Administration (bib0140) 2019 Desfontaine, Guillarme, Francotte, Novakova (bib0065) 2015; 113 U.S. Food & Drug Administration, Center for Drug Evaluation and Research (bib0055) 2018 EMA/526031/2018 (bib0050) 2018 Bartle (bib0070) 1988 EDQM Knowledge Database (10.1016/j.jpba.2019.04.049_bib0135) 2018 World Health Organization (10.1016/j.jpba.2019.04.049_bib0040) 2002 U.S. Food & Drug Administration (10.1016/j.jpba.2019.04.049_bib0020) 2018 European network of OMCLs (10.1016/j.jpba.2019.04.049_bib0145) 2018 Desfontaine (10.1016/j.jpba.2019.04.049_bib0065) 2015; 113 10.1016/j.jpba.2019.04.049_bib0080 U.S. Food & Drug Administration (10.1016/j.jpba.2019.04.049_bib0140) 2019 Schmidtsdorff (10.1016/j.jpba.2019.04.049_bib0125) 2018; 1577 Abdel-Tawab (10.1016/j.jpba.2019.04.049_bib0025) 2018; 158 Lim (10.1016/j.jpba.2019.04.049_bib0100) 2018; 81 U.S. Environmental Protection Agency, Federal Facilities Restoration and Reuse Office (10.1016/j.jpba.2019.04.049_bib0045) 2017 RIS.World Online (10.1016/j.jpba.2019.04.049_bib0130) 2018 10.1016/j.jpba.2019.04.049_bib0010 European network of OMCLs (10.1016/j.jpba.2019.04.049_bib0060) 2018 Buschmann (10.1016/j.jpba.2019.04.049_bib0015) 2019; 159 U.S. Food & Drug Administration, Center for Drug Evaluation and Research (10.1016/j.jpba.2019.04.049_bib0055) 2018 Venkatesan (10.1016/j.jpba.2019.04.049_bib0110) 2014; 48 Galaon (10.1016/j.jpba.2019.04.049_bib0105) 2016; 17 Parr (10.1016/j.jpba.2019.04.049_bib0150) 2019; 164 EMA/526031/2018 (10.1016/j.jpba.2019.04.049_bib0050) 2018 Dispas (10.1016/j.jpba.2019.04.049_bib0075) 2012; 1256 Sung (10.1016/j.jpba.2019.04.049_bib0115) 2010; 27 Barnett (10.1016/j.jpba.2019.04.049_bib0085) 2016; 42 Hu (10.1016/j.jpba.2019.04.049_bib0120) 2016; 310 10.1016/j.jpba.2019.04.049_bib0090 (10.1016/j.jpba.2019.04.049_bib0095) 2017; vol 2 EMA/703416/2018 (10.1016/j.jpba.2019.04.049_bib0030) 2018 International Agency for Research on Cancer (10.1016/j.jpba.2019.04.049_bib0035) 1978; vol. 17 Bartle (10.1016/j.jpba.2019.04.049_bib0070) 1988 10.1016/j.jpba.2019.04.049_bib0005  | 
    
| References_xml | – year: 2019 ident: bib0140 article-title: Laboratory Analysis of Valsartan Products – volume: 310 start-page: 207 year: 2016 end-page: 216 ident: bib0120 article-title: Elevated urinary levels of carcinogenic N-nitrosamines in patients with urinary tract infections measured by isotope dilution online SPE LC–MS/MS publication-title: J. Hazard. Mater. – reference: (Last accessed: 01. April 2019). – reference: Committee for Medicinal Products for Human Use (16. July 2018) CHMP List of questions - To be addressed by the API manufacturers for valsartan-containing medicinal products (Procedure number: EMEA/H/A-31/1471). European Medicines Agency - London, United Kingdom – volume: 159 start-page: 50 year: 2019 end-page: 54 ident: bib0015 article-title: Noch mehr Nitrosamine - NDMA, NDEA, NDIPA - wie kommen die Verunreinigungen in die Sartane? publication-title: In: Deutsche Apotheker Zeitung – volume: 17 start-page: 74 year: 2016 end-page: 82 ident: bib0105 article-title: New LC-MS/MS method for the determination of eight nitrosamines in drinking water publication-title: J Environ Prot Ecol – volume: 42 year: 2016 ident: bib0085 article-title: Stimuli article: analytical target profile (ATP): structure and application throughout the analytical lifecycle publication-title: Pharmacopeial Forum – volume: 81 start-page: 465 year: 2018 end-page: 480 ident: bib0100 article-title: Risk assessment of N-nitrosodiethylamine (NDEA) and N-nitrosodiethanolamine (NDELA) in cosmetics publication-title: J Toxicol Environ Health A – volume: 113 start-page: 56 year: 2015 end-page: 71 ident: bib0065 article-title: Supercritical fluid chromatography in pharmaceutical analysis publication-title: J. Pharm. Biomed. Anal. – volume: 164 start-page: 536 year: 2019 end-page: 549 ident: bib0150 article-title: NDMA impurity in valsartan and other pharmaceutical products: analytical methods for the determination of N-nitrosamines publication-title: J. Pharm. Biomed. Anal. – year: 2018 ident: bib0135 article-title: Valsartan - Monograph Number: 02423. EDQM – year: 1988 ident: bib0070 article-title: Theory and principles of supercritical fluid chromatography publication-title: Supercritical Fluid Chromatography – year: 2018 ident: bib0060 article-title: OMCLs Release Three Methods for Determination of NDMA in Sartans – year: 2018 ident: bib0055 article-title: GC/MS Headspace Method for Detection of NDMA in Valsartan Drug Substance – year: 2018 ident: bib0145 article-title: Update on Detection of Nitrosamines in Valsartan and Validated Testing Method – volume: 158 start-page: 2898 year: 2018 end-page: 2902 ident: bib0025 article-title: Valsartan: ZL findet NDMA in Tabletten publication-title: Pharm. (1856) – volume: 48 start-page: 5085 year: 2014 end-page: 5092 ident: bib0110 article-title: Detection and occurrence of N-Nitrosamines in archived biosolids from the targeted national sewage sludge survey of the U.S. Environmental protection agency publication-title: Environ. Sci. Technol. – volume: 27 start-page: 1745 year: 2010 end-page: 1754 ident: bib0115 article-title: Liquid chromatography-tandem mass spectrometry determination of N-nitrosamines released from rubber or elastomer teats and soothers publication-title: Food Addit. Contam. Part A – volume: vol. 17 year: 1978 ident: bib0035 publication-title: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans - Some N-Nitroso Compounds – reference: European Pharmacopoeia. 9th edition. Strasbourg: Council of Europe. – year: 2002 ident: bib0040 article-title: N-Nitrosodimethylamine, Concise International Chemical Assessment Document 38 – volume: vol 2 year: 2017 ident: bib0095 publication-title: United States Pharmacopeia and National Formulary (USP 40-NF 35) – volume: 1256 start-page: 253 year: 2012 end-page: 260 ident: bib0075 article-title: Innovative green supercritical fluid chromatography development for the determination of polar compounds publication-title: J. Chromatogr. A – year: 2017 ident: bib0045 article-title: Technical Fact Sheet - N-Nitrosodimethylamine – year: 2018 ident: bib0050 article-title: Update on Review of Recalled Valsartan Medicines – year: 2018 ident: bib0130 article-title: Update on the Review of CEP Applications for sartans.EDQM – reference: . – year: 2018 ident: bib0020 article-title: FDA Provides Update on Its Ongoing Investigation Into Valsartan Products; and Reports on the Finding of an Additional Impurity Identified in One Firm’s Already Recalled Products – year: 2018 ident: bib0030 article-title: EU Authorities Take Further Action in Ongoing Review of Sartans: Zheijiang Huahai Placed Under Increased Supervision; Aurobindo Pharma Stopped From Supplying Irbesartan to the EU – reference: FDA updates on angiotensin II receptor blocker (ARB) recalls including valsartan, losartan and irbesartan. – volume: 1577 start-page: 38 year: 2018 end-page: 46 ident: bib0125 article-title: Structure assisted impurity profiling for rapid method development in liquid chromatography publication-title: J. Chromatogr. A – reference: Guideline, ICH Harmonised Tripartite - Proceedings of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, Geneva, Switzerland. – ident: 10.1016/j.jpba.2019.04.049_bib0090 – ident: 10.1016/j.jpba.2019.04.049_bib0080 – year: 2018 ident: 10.1016/j.jpba.2019.04.049_bib0060 – volume: 159 start-page: 50 year: 2019 ident: 10.1016/j.jpba.2019.04.049_bib0015 article-title: Noch mehr Nitrosamine - NDMA, NDEA, NDIPA - wie kommen die Verunreinigungen in die Sartane? publication-title: In: Deutsche Apotheker Zeitung – volume: 42 year: 2016 ident: 10.1016/j.jpba.2019.04.049_bib0085 article-title: Stimuli article: analytical target profile (ATP): structure and application throughout the analytical lifecycle publication-title: Pharmacopeial Forum – volume: vol 2 year: 2017 ident: 10.1016/j.jpba.2019.04.049_bib0095 – year: 2017 ident: 10.1016/j.jpba.2019.04.049_bib0045 – volume: 48 start-page: 5085 year: 2014 ident: 10.1016/j.jpba.2019.04.049_bib0110 article-title: Detection and occurrence of N-Nitrosamines in archived biosolids from the targeted national sewage sludge survey of the U.S. Environmental protection agency publication-title: Environ. Sci. Technol. doi: 10.1021/es5001352 – volume: 27 start-page: 1745 year: 2010 ident: 10.1016/j.jpba.2019.04.049_bib0115 article-title: Liquid chromatography-tandem mass spectrometry determination of N-nitrosamines released from rubber or elastomer teats and soothers publication-title: Food Addit. Contam. Part A doi: 10.1080/19440049.2010.508184 – year: 2018 ident: 10.1016/j.jpba.2019.04.049_bib0130 – volume: 81 start-page: 465 year: 2018 ident: 10.1016/j.jpba.2019.04.049_bib0100 article-title: Risk assessment of N-nitrosodiethylamine (NDEA) and N-nitrosodiethanolamine (NDELA) in cosmetics publication-title: J Toxicol Environ Health A doi: 10.1080/15287394.2018.1460782 – year: 2018 ident: 10.1016/j.jpba.2019.04.049_bib0050 – year: 2018 ident: 10.1016/j.jpba.2019.04.049_bib0055 – volume: 113 start-page: 56 year: 2015 ident: 10.1016/j.jpba.2019.04.049_bib0065 article-title: Supercritical fluid chromatography in pharmaceutical analysis publication-title: J. Pharm. Biomed. Anal. doi: 10.1016/j.jpba.2015.03.007 – year: 2018 ident: 10.1016/j.jpba.2019.04.049_bib0145 – ident: 10.1016/j.jpba.2019.04.049_bib0010 – year: 2018 ident: 10.1016/j.jpba.2019.04.049_bib0135 – year: 1988 ident: 10.1016/j.jpba.2019.04.049_bib0070 article-title: Theory and principles of supercritical fluid chromatography – year: 2018 ident: 10.1016/j.jpba.2019.04.049_bib0020 – volume: 1256 start-page: 253 year: 2012 ident: 10.1016/j.jpba.2019.04.049_bib0075 article-title: Innovative green supercritical fluid chromatography development for the determination of polar compounds publication-title: J. Chromatogr. A doi: 10.1016/j.chroma.2012.07.043 – year: 2019 ident: 10.1016/j.jpba.2019.04.049_bib0140 – year: 2002 ident: 10.1016/j.jpba.2019.04.049_bib0040 – ident: 10.1016/j.jpba.2019.04.049_bib0005 – volume: 1577 start-page: 38 year: 2018 ident: 10.1016/j.jpba.2019.04.049_bib0125 article-title: Structure assisted impurity profiling for rapid method development in liquid chromatography publication-title: J. Chromatogr. A doi: 10.1016/j.chroma.2018.09.044 – volume: 17 start-page: 74 year: 2016 ident: 10.1016/j.jpba.2019.04.049_bib0105 article-title: New LC-MS/MS method for the determination of eight nitrosamines in drinking water publication-title: J Environ Prot Ecol – volume: vol. 17 year: 1978 ident: 10.1016/j.jpba.2019.04.049_bib0035 – volume: 310 start-page: 207 year: 2016 ident: 10.1016/j.jpba.2019.04.049_bib0120 article-title: Elevated urinary levels of carcinogenic N-nitrosamines in patients with urinary tract infections measured by isotope dilution online SPE LC–MS/MS publication-title: J. Hazard. Mater. doi: 10.1016/j.jhazmat.2016.02.048 – volume: 158 start-page: 2898 year: 2018 ident: 10.1016/j.jpba.2019.04.049_bib0025 article-title: Valsartan: ZL findet NDMA in Tabletten publication-title: Pharm. (1856) – volume: 164 start-page: 536 year: 2019 ident: 10.1016/j.jpba.2019.04.049_bib0150 article-title: NDMA impurity in valsartan and other pharmaceutical products: analytical methods for the determination of N-nitrosamines publication-title: J. Pharm. Biomed. Anal. doi: 10.1016/j.jpba.2018.11.010 – year: 2018 ident: 10.1016/j.jpba.2019.04.049_bib0030  | 
    
| SSID | ssj0005194 | 
    
| Score | 2.4812894 | 
    
| Snippet | •Simultaneous detection of nitrosamines and monographed impurities in sartans•Novel SFC approach for large group of nitrosamines•High sensitivity and... Since July 2018, the pharmacological class of "sartans" has been the subject of considerable media and analytical interest, as it became known that they are...  | 
    
| SourceID | proquest pubmed crossref elsevier  | 
    
| SourceType | Aggregation Database Index Database Enrichment Source Publisher  | 
    
| StartPage | 151 | 
    
| SubjectTerms | Angiotensin II Type 1 Receptor Blockers - analysis Chromatography, Supercritical Fluid Diethylnitrosamine - analysis Dimethylnitrosamine - analysis Drug Contamination Limit of Detection Losartan - analysis Nitrosamines Nitrosamines - analysis Propylamines - analysis Quality Control Quality-by-Design (QbD) Reference Standards Risk Assessment Sartans Supercritical fluid chromatography (SFC) Valsartan - analysis  | 
    
| Title | Simultaneous detection of nitrosamines and other sartan-related impurities in active pharmaceutical ingredients by supercritical fluid chromatography | 
    
| URI | https://dx.doi.org/10.1016/j.jpba.2019.04.049 https://www.ncbi.nlm.nih.gov/pubmed/31174128 https://www.proquest.com/docview/2242163391  | 
    
| Volume | 174 | 
    
| hasFullText | 1 | 
    
| inHoldings | 1 | 
    
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Baden-Württemberg Complete Freedom Collection (Elsevier) customDbUrl: eissn: 1873-264X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0005194 issn: 0731-7085 databaseCode: GBLVA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection customDbUrl: eissn: 1873-264X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0005194 issn: 0731-7085 databaseCode: .~1 dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: ScienceDirect Freedom Collection 2025 customDbUrl: eissn: 1873-264X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0005194 issn: 0731-7085 databaseCode: ACRLP dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: ScienceDirect Journal Collection customDbUrl: eissn: 1873-264X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0005194 issn: 0731-7085 databaseCode: AIKHN dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVLSH databaseName: Elsevier Journals customDbUrl: mediaType: online eissn: 1873-264X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0005194 issn: 0731-7085 databaseCode: AKRWK dateStart: 19950101 isFulltext: true providerName: Library Specific Holdings  | 
    
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NT9wwELUQXHqpCv3alqKpVHEp6caJHSdHhIq2rYSQAImb5cSOCIJstJs97IV_wf_tjOMAlVoOlXJJ4iiWZ2y_Sd68YeyLqmSZuqKOjE1EJOoap5QTMrImd9Y5Zaraq32eZLML8fNSXm6wozEXhmiVYe0f1nS_Wocr0zCa065ppmfonFwRYkCnzFVCip9CKKpi8O3uCc2D-2KI1Dii1iFxZuB4XXclaQ_xwsudkp7m3zenf4FPvwkdv2IvA3qEw6GD22zDtTts_3SQn14fwPljNtXyAPbh9FGYev2a3Z81xB80rcNwH6zrPQ2rhXkNOLGxR-aWSPBgWgs-MQuWOBSmjXzCi7PQ3HZU7A6Da2haMH6phO7q6VdxvIERPNHI-iWUa1iuOreoQj0FqG9WjYXqajFHoBzEst-wi-Pv50ezKJRliKpUZn3ErcoUmrEQic1jl0tlapMom5eJq1xa8DyjUqTcqMrWVJO0tDYrLCEnYSU36Vu22c5b955BbMu4qIyKHeKgWMYlxkuFQUTmMAoUSk4YH-2hq6BZTqUzbvRITrvWZENNNtSxwKOYsK8Pz3SDYsezreVoZv2H32ncUp597vPoExonJP1lGaynE_rJnqU4DhP2bnCWh36kHANARAQf_vOtH9kLOiO-Co932Wa_WLlPCIr6cs97_R7bOvzxa3byG_C9EHQ | 
    
| linkProvider | Elsevier | 
    
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwELVKOcAF8c3yOUioFxo2Tuw4OaKKaoFSVepW6s1yYkdN1Waj3exhL_wL_i8zjtMWCXpAyilxFMsztt_Eb94w9kFVskxdUUfGJiISdY1TygkZWZM765wyVe3VPg-z2Yn4dipPt9jemAtDtMqw9g9rul-tw51pGM1p1zTTY3ROrggxoFPmKknvsLtCJooisE8_b_A8uK-GSK0jah4yZwaS13lXkvgQL7zeKQlq_n13-hf69LvQ_kP2IMBH-Dz08BHbcu1jtnM06E9vdmF-nU612oUdOLpWpt48Yb-OGyIQmtZhvA_W9Z6H1cKiBpzZ2CNzSSx4MK0Fn5kFKxwL00Y-48VZaC47qnaH0TU0LRi_VkJ3dvO3OD7AEJ54ZP0Kyg2s1p1bVqGgAtQX68ZCdbZcIFIOatlP2cn-l_neLAp1GaIqlVkfcasyhXYsRGLz2OVSmdokyuZl4iqXFjzPqBYpN6qyNRUlLa3NCkvQSVjJTfqMbbeL1r1gENsyLiqjYodAKJZxiQFTYRCSOQwDhZITxkd76CqIllPtjAs9stPONdlQkw11LPAqJuzj1TvdINlxa2s5mln_4Xga95Rb33s_-oTGGUnHLIP1dEKn7FmK4zBhzwdnuepHyjECREjw8j-_-o7dm81_HOiDr4ffX7H79ITIKzx-zbb75dq9QYTUl2_9DPgNGfoSCQ | 
    
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Simultaneous+detection+of+nitrosamines+and+other+sartan-related+impurities+in+active+pharmaceutical+ingredients+by+supercritical+fluid+chromatography&rft.jtitle=Journal+of+pharmaceutical+and+biomedical+analysis&rft.au=Schmidtsdorff%2C+Sebastian&rft.au=Schmidt%2C+Alexander+H.&rft.date=2019-09-10&rft.pub=Elsevier+B.V&rft.issn=0731-7085&rft.eissn=1873-264X&rft.volume=174&rft.spage=151&rft.epage=160&rft_id=info:doi/10.1016%2Fj.jpba.2019.04.049&rft.externalDocID=S0731708518328723 | 
    
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0731-7085&client=summon | 
    
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0731-7085&client=summon | 
    
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0731-7085&client=summon |